Search details
1.
MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies.
Clin Chem
; 70(2): 434-443, 2024 02 07.
Article
in English
| MEDLINE | ID: mdl-38069911
2.
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study.
JAAD Int
; 15: 105-114, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38500872
3.
Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.
bioRxiv
; 2024 Mar 26.
Article
in English
| MEDLINE | ID: mdl-38405985
4.
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
EClinicalMedicine
; 65: 102290, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37965433
5.
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.
J Clin Oncol
; 40(1): 12-23, 2022 01 01.
Article
in English
| MEDLINE | ID: mdl-34752147
6.
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
JAMA Oncol
; 7(5): 744-748, 2021 05 01.
Article
in English
| MEDLINE | ID: mdl-33764387
7.
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
EClinicalMedicine
; 71: 102564, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38572079
Results
1 -
7
de 7
1
Next >
>>